H Lundbeck A/S

Common Name
H Lundbeck
Country
Denmark
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
5,700
Ticker
HLUN A
Exchange
NASDAQ COPENHAGEN A/S
Description
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and inter...

H Lundbeck's Financial Statements Preview

Below are the financial statements of H Lundbeck, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Interested in getting early access to our real-time standardized financial datafeed?
Learn More
All figures in billions of DKK
2024 2024-01-01 - 2024-12-31
2023 2023-01-01 - 2023-12-31
Revenue
22a
19.91a
Cost of sales
-4.23a
-4.49a
Gross profit
17.77a
15.43a
Sales and distribution costs
-8.15a
-7.48a
Administrative expenses
-1.44a
-1.29a
Research and development costs
-4.5a
-3.46a
Other operating expenses, net
-0.42a
0a
Profit from operations (EBIT)
3.27a
3.2a
Financial income
0.67a
0.09a
Financial expenses
-0.22a
-0.3a
Profit before tax
3.72a
2.99a
Tax on profit for the year
-0.58a
-0.7a
Profit for the year
3.14a
2.29a
Download Data

Verified Sources Behind H Lundbeck’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore H Lundbeck’s data sources below and access millions more through our Disclosure Search.

a. H Lundbeck's Annual Report 2024
a. H Lundbeck's Annual Report 2024
Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

Tracenable is building real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?